Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767247 | 0.90 | CTSK (0.36) | CTSKCTSLCTSSCNR1CNR2 | |
| SCHEMBL7480516 | 0.87 | CTSK (0.41) | CTSKCTSLCTSSCNR1CNR2 | |
| SCHEMBL5092902 | 0.79 | CTSK (0.45) | CTSKCTSLCTSSCNR1CNR2 | |
| SCHEMBL5092894 | 0.78 | CTSK (0.35) | CTSKCTSLCTSSCNR1CNR2 | |
| SCHEMBL5105797 | 0.78 | CTSK (0.38) | CTSKCTSLCTSSCNR1CNR2 | |
| SCHEMBL7451271 | 0.73 | CTSK (0.38) | CTSKCTSLCTSS | |
| SCHEMBL7455803 | 0.72 | CTSK (0.37) | CTSKCTSLCTSS | |
| SCHEMBL7565531 | 0.72 | SIGMAR1 (0.43) | CTSKCTSLCTSS | |
| SCHEMBL7565521 | 0.72 | SIGMAR1 (0.43) | CTSKCTSLCTSS | |
| SCHEMBL6765207 | 0.71 | CYP3A4 (0.45) | CTSKPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.